Okay, let's tackle this question about AML prognostic factors. The user wants me to explain why a certain answer is correct and why the others are wrong. First, I need to recall the core concept here. Acute Myeloid Leukemia (AML) has various prognostic factors that determine treatment outcomes. The question is asking which of the options is NOT a good prognostic factor.

So, the core concept is understanding the prognostic factors in AML. Good factors include things like age under 60, certain cytogenetic abnormalities like t(8;21) or inv(16), and normal karyotype. Poor prognostic factors include age over 60, certain mutations like FLT3-ITD, and complex karyotype.

The correct answer here would be the option that's a poor prognostic factor. Let's say the options are something like: A. t(8;21), B. Age <60, C. Normal karyotype, D. FLT3-ITD mutation. Then the correct answer is D because FLT3-ITD is bad. For the wrong options, A and C are good because they're favorable cytogenetics. B is good because younger patients respond better. D is bad, so it's the exception. The clinical pearl would be to remember that FLT3-ITD is a high-risk marker in AML. I need to structure the explanation with the required sections, making sure each part is concise and covers the necessary points without being too wordy. Check the character count to stay within limits. Also, use bold for key terms and avoid markdown headings. Make sure each section is clear and addresses the question correctly.

**Core Concept**
Prognostic factors in Acute Myeloid Leukemia (AML) determine treatment response and survival. Favorable factors include specific cytogenetic abnormalities (e.g., t(8;21), inv(16)), normal karyotype, and age 60.

**Why the Correct Answer is Right**
FLT3-ITD (FMS-like tyrosine kinase 3 internal tandem duplication) is a **poor prognostic marker** in AML. This mutation causes constitutive activation of the FLT3 receptor tyrosine kinase, leading to uncontrolled cell proliferation and resistance to chemotherapy. Patients with FLT3-ITD mutations have higher relapse rates and worse overall survival compared to those with wild-type FLT3.

**Why Each Wrong Option is Incorrect**
**Option A:** t(8;21) is a **favorable cytogenetic abnormality** in AML, associated with high remission rates and better outcomes due to sensitivity to chemotherapy.
**Option B:** Age <60 is a **strong prognostic factor** because younger patients tolerate aggressive treatment better and have more effective marrow regeneration. **Option C:** Normal karyotype (non-complex) is a **neutral or favorable** prognostic factor compared to complex karyotypes, which correlate with poor outcomes. **Clinical Pearl / High-Yield Fact** Remember the **"3 Ws" of AML prognosis**: **W**ild-type NPM1 (better

✓ Correct Answer: C. Acute megakaryoblastic leukemia